



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24  
CIN No. L74899DL1978PLC009181

Date: June 30<sup>th</sup>, 2021

To, The Department of Corporate Services- Listing BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
<b>Scrip Code: 507789</b>	<b>Symbol: JAGSNPHARM</b>

**SUBJECT:- OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON JUNE 30<sup>TH</sup>, 2021**

Dear Sir,

This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Wednesday, the 30<sup>th</sup> Day of June, 2021), commenced at 12:00 Noon and concluded on 03:45 P.M. at registered office, have inter alia, approved and taken on record the following:

1. Pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Audited Standalone Financial Results of the Company for the Quarter and year ended 31<sup>st</sup> March, 2021;
2. Audit Report for the Quarter and year ended 31<sup>st</sup> March, 2021;
3. Notice of 42<sup>nd</sup> Annual General Meeting.
4. Approved the Draft Directors Report together with management discussion along with Report on Corporate Governance.
5. Availment of E- Voting facility from NSDL.
6. Appointment of Scrutinizer for conducting E-voting.
7. Fixed the Book Closure date and cut- off date for the purpose of Annual General Meeting and e-voting.
8. The Board recommended dividend @ 20% per Equity Shares of face value of Rs. 5/- each, i.e. Re. 1/- per Equity Share.
9. Other Agenda items.

Kindly take the above on record & oblige.

For JAGSONPAL PHARMACEUTICALS LIMITED

  
Nandita Singh  
Company Secretary cum Compliance Officer







## **JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. Office : T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24  
CIN No. L74899DL1978PLC009181

### **Declaration With Regard To Unmodified Opinion On Audited Financial Results (Standalone) For The Quarter And Year Ended March 31, 2019**

With respect to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016, I, **Nandita Singh**, Company Secretary of the company “**Jagsonpal Pharmaceuticals Limited**” (the “Company”) with regard to the submission of the Annual Audited Financial Results (Standalone) for the Quarter and Financial year ended 31.03.2021 with Bombay Stock Exchange & National Stock Exchange, hereby declare that the Auditors report issued by Statutory Auditors of the Company, does not contain any modified opinion that seeks further clarification with respect to its impact thereon.

**For JAGSONPAL PHARMACEUTICALS LIMITED**

**Nandita Singh**  
**Company Secretary cum Compliance Officer**

**Date: 30.06.2021**  
**Place: New Delhi**



**Independent Auditor's report on Audited Standalone Quarterly and Year to Date Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of Jagsonpal Pharmaceuticals Limited**

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone annual financial results ("the Statement") of **JAGSONPAL PHARMACEUTICALS LIMITED** ("the company") for the quarter and year ended 31<sup>st</sup> March, 2021, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended 31<sup>st</sup> March, 2021.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the





preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For H L Bansal & Co.**  
Chartered Accountants  
(Firm's Registration No. 008563N)



**HIRA LAL BANSAL**  
Partner


(Membership No. 086990)  
UDIN : 21086990 AAAADBS924

Place : Delhi

Date : 30/06/2021



Statement of Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2021						
Particulars	Standalone			Rs. in lakhs		
	Quarter Ended			12 Months	12 Months	
	31.03.2021	31.03.2020	31.12.2020	Year Ended	Year Ended	
	Audited	Audited	Unaudited	Audited	Audited	
31.03.2021	31.03.2020	31.12.2020	31.03.2021	31.03.2020		
<b>1</b>	<b>Income from operations</b>					
a	Gross Sales/Revenue from Operations	4283.65	2951.75	5710.43	18794.56	15856.78
b	Other Operating Income	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from operations</b>	<b>4283.65</b>	<b>2951.75</b>	<b>5710.43</b>	<b>18794.56</b>	<b>15856.78</b>
<b>2</b>	<b>Other Income</b>					
		266.05	76.04	53.48	439.33	252.62
<b>3</b>	<b>Total Income [ 1+2]</b>					
		<b>4549.70</b>	<b>3027.79</b>	<b>5763.91</b>	<b>19233.89</b>	<b>16109.40</b>
<b>4</b>	<b>Expenses</b>					
a	Cost of materials consumed	1159.70	505.01	1172.94	3863.45	3678.48
b	Purchases of stock-in-trade	1114.36	343.96	1403.74	3686.19	1815.19
c	Changes in inventories of finished goods, work in progress and Stock in trade	-769.30	-66.62	-47.90	527.97	124.99
d	Excise Duty	0.00		0.00	0.00	0.00
d	Employee benefits expenses	1117.14	1014.37	1533.20	5398.12	5037.42
e	Finance Cost	13.01	14.71	13.56	51.35	51.41
f	Depreciation and amortisation expense	26.26	31.70	27.43	108.60	112.98
g	Other expenses	1150.22	1032.68	1000.18	3410.98	4347.45
	<b>Total expenses</b>	<b>3811.39</b>	<b>2875.81</b>	<b>5103.15</b>	<b>17046.66</b>	<b>15167.92</b>
<b>5</b>	<b>Profit before exceptional items and taxes (3-4)</b>					
		<b>738.31</b>	<b>151.98</b>	<b>660.76</b>	<b>2187.23</b>	<b>941.48</b>
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
<b>7</b>	<b>Profit before tax [5-6]</b>					
		<b>738.31</b>	<b>151.98</b>	<b>660.76</b>	<b>2187.23</b>	<b>941.48</b>
8	Tax expense	228.41	-3.50	117.73	481.40	154.40
<b>9</b>	<b>Net Profit for the period [7-8]</b>					
		<b>509.90</b>	<b>155.48</b>	<b>543.03</b>	<b>1705.83</b>	<b>787.08</b>
10	Other Comprehensive Income					
A	(i) Items that will not be classified to profit or loss	21.39	0.00	0.00	21.39	0.00
	(ii) Income tax relating to items that will not be reclassified to profit and	-6.23	0.00	0.00	-6.23	0.00
<b>11</b>	<b>Total Other Comprehensive Income [A(i) + A(ii)]</b>					
		<b>15.16</b>	<b>0.00</b>	<b>0.00</b>	<b>15.16</b>	<b>0.00</b>
<b>12</b>	<b>Total Comprehensive Income [9+11]</b>					
		<b>525.06</b>	<b>155.48</b>	<b>543.03</b>	<b>1720.99</b>	<b>787.08</b>
13	Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90
<b>14</b>	<b>Earnings Per Share (before and after extraordinary items)</b>					
	<b>(of Rs 5/- each)</b>					
a.	Basic (Rs.)	1.95	0.59	2.07	6.51	3.00
b.	Diluted (Rs.)	1.95	0.59	2.07	6.51	3.00



(Rs in lakhs)

## Statement of Assets and Liabilities

Particulars	As on 31.03.2021	As on 31.03.2020
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property , Plant and Equipment	2334.66	2206.02
(b) Capital Work-in-Progress	0.00	190.34
(c) Goodwill	3.00	3.00
(d) Intangible assets under development		
	234.53	234.53
(e) Financial assets		
(i) Investments	1205.84	1138.68
(f) Other non-current assets	594.50	1466.15
<b>Total non-current assets</b>	<b>4372.53</b>	<b>5238.72</b>
<b>2 Current assets</b>		
(a) Inventories	2972.45	2932.50
(b) Financial assets		
(i) Trade receivables	1266.40	2145.34
(ii) Cash and Cash equivalents	5894.29	3981.30
(iii) Bank balances other than (ii) above	128.69	67.21
(c) Other current assets	1785.88	504.30
<b>Total current assets</b>	<b>12047.71</b>	<b>9630.65</b>
<b>TOTAL ASSETS</b>	<b>16420.24</b>	<b>14869.37</b>

<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	10883.01	9793.49
<b>Total Equity</b>	<b>12192.91</b>	<b>11103.39</b>
<b>LIABILITIES</b>		
<b>1 Non-current liabilities</b>		
(a) Deferred tax liabilities (Net)	185.86	309.16
(b) Non current borrowings/Provision	1.80	0.00
<b>Non-current liabilities</b>	<b>187.66</b>	<b>309.16</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Trade payables	1804.99	1170.93
(ii) Short term borrowings	678.79	640.37
(b) Other current liabilities	1173.74	815.54
(c) Provision for tax	382.15	829.98
<b>Total current liabilities</b>	<b>4039.67</b>	<b>3456.82</b>
<b>Total Liabilities</b>	<b>4227.33</b>	<b>3765.98</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>16420.24</b>	<b>14869.37</b>



**NOTES:**

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on June 30, 2021. The statutory auditors have expressed an unmodified opinion on the aforesaid results,

2. In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

3. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

4. The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.

6. Provision for taxation includes provision for current tax.

7. The Board of Directors has proposed a dividend of Re. 1 per Equity Shares of Face value of Rs 5/- each (i.e. 20%).

8. Figures for the quarter ended 31st March 2020 are balancing figures between the audited figures in respect of full financial year ended 31st March 2021 and published figure upto 3rd quarter ended 31st December 2020.



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

A handwritten signature in black ink, appearing to read 'Rajpal Singh Kochhar'.

Place : New Delhi  
Date : 30 June, 2021

Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492



**Jagsonpal Pharmaceuticals Limited**  
**Standalone Balance Sheet as at 31st March 2021**  
(All amounts in Indian Rupees lacs, unless stated otherwise)

	Notes	As at 31st March 2021	As at 31 March 2020
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3	2,334.66	2,206.02
Capital work-in-progress	3	-	190.34
Intangible assets	4	237.53	237.53
<b>Financial assets</b>			
(i) Investments	5A	1,205.84	1,138.68
(ii) Loans	6A	44.22	51.72
(iii) Other	7A	28.61	-
Non-current tax assets (net)	8	457.76	1,401.47
Deferred tax assets (net)	9	-	-
Other non-current assets	10A	63.91	12.96
		<b>4,372.53</b>	<b>5,238.72</b>
<b>Current assets</b>			
Inventories	11	2,972.45	2,932.50
<b>Financial assets</b>			
(i) Investments	5B	325.07	-
(ii) Loans	6B	26.77	32.89
(iii) Trade receivables	12	1,266.40	2,145.34
(iv) Cash and cash equivalents	13	5,894.29	3,981.30
(v) Bank balances other than (iv) above	14	128.69	67.21
(vi) Other	7B	25.03	36.09
Other current assets	10B	1,409.01	435.32
		<b>12,047.71</b>	<b>9,630.65</b>
<b>Total assets</b>		<b>16,420.24</b>	<b>14,869.37</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Equity share capital	15	1,309.90	1,309.90
Other equity	16	10,883.01	9,793.49
<b>Total equity</b>		<b>12,192.91</b>	<b>11,103.39</b>
<b>Non-current liabilities</b>			
<b>Financial liabilities</b>			
(i) Borrowings	17A	-	-
(ii) Lease liabilities	18	-	-
Provisions	19	1.80	-
Deferred tax Lib(net)	9	185.86	309.16
		<b>187.66</b>	<b>309.16</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
(i) Borrowings	17B	678.79	640.37
(ii) Trade payables			
-total outstanding dues of micro enterprises		218.23	275.98
-total outstanding dues of creditor other than micro enterprises and small	21	1,586.76	894.95
(iii) Lease liabilities	18	-	-
(iv) Other financial liabilities	22	438.25	390.71
Provisions	19	84.68	-
Government grants	20	-	-
Current tax liabilities	23	382.15	829.98
Other current liabilities	24	650.81	424.83
		<b>4,039.67</b>	<b>3,456.82</b>
<b>Total equity and liabilities</b>		<b>16,420.24</b>	<b>14,869.37</b>
<b>Summary of significant accounting poli</b>	2		

The accompanying notes form an integral part of the financial statements

As per our report of even date

**For H L Bansal and CO.**

**Chartered Accountants**

**FRN. NO. 008563N**

**Hira Lal Bansal**

**Partner**

**M.No. 086990**

**Place: New Delhi**

**Date: 30 June, 2021**

**UDIN: 21086990 AAAA DB5924**



For and on behalf of the Board of Directors  
For Jagsonpal Pharmaceuticals Limited

**Rajpal Singh Kochhar**

**DIN 00059492**

**Chairman & Managing Director**

**S.K. Dudeja**

**S.K. Dudeja**  
**Chief Financial Officer**

**Nandita Singh**  
**Company Secretary**

**Jagsonpal Pharmaceuticals Limited**  
**Standalone Statement of Profit and Loss for the Period ended 31st March 2021**  
(All amounts in Indian Rupees lacs, unless stated otherwise)

	Notes	For the year ended 31st March 2021	For the year ended 31 March 2020
<b>Income</b>			
Revenue from operations	25	18,794.56	15,856.78
Other income	26	439.33	252.62
<b>Total income</b>		<b>19,233.89</b>	<b>16,109.40</b>
<b>Expenses</b>			
Cost of raw and packing materials consumed	27	3,863.45	3,678.48
Purchase of traded goods		3,686.19	1,815.19
(Increase)/ decrease in inventories of finished goods, work-in-progress and traded goods	28	527.97	124.99
Excise Duty on sale of goods		-	-
Employee benefits expense	29	5,398.12	5,037.42
Depreciation and amortisation expense	30	108.60	112.98
Finance costs	31	51.35	51.41
Other expenses	32	3,410.98	4,347.45
<b>Total expenses</b>		<b>17,046.66</b>	<b>15,167.92</b>
<b>Profit before tax</b>		<b>2,187.23</b>	<b>941.48</b>
Income tax expense	33		
Current Tax		604.70	157.15
Add: MAT credit written off of earlier years		-	-
<b>Net current tax</b>		<b>604.70</b>	<b>157.15</b>
Adjustment of tax relating to earlier periods		-	-
Deferred tax		(123.30)	(2.75)
<b>Total tax expense</b>		<b>481.40</b>	<b>154.40</b>
<b>Profit for the year (A)</b>		<b>1,705.83</b>	<b>787.08</b>
<b>Other comprehensive income</b>			
Items that will not be reclassified to profit or loss in subsequent periods:			
Re-measurement losses on defined benefit plans		21.39	-
Income tax effect	33	(6.23)	-
<b>Other comprehensive income for the year, net of tax (B)</b>		<b>15.16</b>	<b>-</b>
<b>Total comprehensive income for the year (A+B)</b>		<b>1,720.99</b>	<b>787.08</b>
<b>Earnings per equity share</b>			
Basic earnings per equity share (INR)	34	6.51	3.00
Diluted earnings per equity share (INR)		6.51	3.00
<b>Summary of significant accounting policies</b>			
2			

The accompanying notes form an integral part of the financial statements

As per our report of even date

**For H L Bansal and CO.**

Chartered Accountants

FRN NO. 008563N

*H L Bansal*

Hira Lal Bansal

Partner

M.No: 086990

Place: New Delhi

Date: 30 June, 2021

UDIN: 21086990AAAA DB5924

**For and on behalf of the Board of Directors**

For Jagsonpal Pharmaceuticals Limited



*Rajpal Singh Kochhar*

Rajpal Singh Kochhar

DIN 00059492

Chairman & Managing Director

*S.K. Dudeja*

S.K. Dudeja  
Chief Financial Officer

*Nandita Singh*

Nandita Singh  
Company Secretary

**Jagsonpal Pharmaceuticals Limited**  
**Standalone Cash flow statement for the period ended 31st March 2021**  
(All amounts in Indian Rupees lacs, unless stated otherwise)

	For the year ended 31st March 2021	For the year ended 31 March 2020
<b>A. Cash flow from operating activities</b>		
<b>Net Profit before tax</b>	<b>2,187.23</b>	<b>941.48</b>
Other Comprehensive Income	15.16	
Depreciation and amortisation expense	108.60	112.98
Loss/ (profit) on sale of property, plant and equipment	-	(1.60)
Interest income	(299.24)	(216.80)
Interest expense	51.35	51.41
Prepaid Expense	12.96	-
Fair value gain on financial instruments at fair value through profit or loss	25.05	-
Deferred tax liability reduced	(123.30)	(2.75)
<b>Operating profit before working capital changes</b>	<b>1,977.81</b>	<b>884.72</b>
<b>Movements in working capital:</b>		
Decrease / (increase) in trade receivables	878.94	(70.32)
Decrease / (increase) in inventories	(39.95)	336.76
(Decrease / (increase) in other financial assets	(3.93)	(21.89)
Decrease / (increase) in other assets	(973.70)	6.59
(Decrease) / increase in trade payables	634.06	(15.11)
(Decrease) / increase in provisions	86.48	-
(Decrease) / increase in other financial liabilities	85.97	32.80
(Decrease / (increase) in tax assets	1,194.80	(21.47)
(Decrease) / increase in tax liabilities	(929.22)	(19.07)
(Decrease) / increase in other liabilities	225.98	255.52
<b>Cash generated from operations</b>	<b>3,137.24</b>	<b>1,368.53</b>
Income Tax paid	(315.00)	(180.00)
<b>Net cash flow from operating activities (A)</b>	<b>2,822.24</b>	<b>1,188.53</b>
<b>B. Cash flow from investing activities</b>		
Net of Sale/ Purchase of property, plant and equipment and intangible assets (including capital work-in-progress)	(46.91)	(185.47)
Purchase of investments	(417.28)	(1,138.63)
Interest received	237.76	216.80
<b>Net cash (used in) / from investing activities (B)</b>	<b>(226.43)</b>	<b>(1,107.30)</b>
<b>C. Cash flow from financing activities</b>		
Interest paid	(51.35)	(51.41)
Change in Equity	(369.47)	-
Dividend	(262.00)	(131.00)
<b>Net cash from/ (used in) financing activities (C)</b>	<b>(682.82)</b>	<b>(182.41)</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+ B+C)</b>	<b>1,912.99</b>	<b>(101.18)</b>
Effect of exchange differences on cash and cash equivalents held in foreign currency	-	
Cash and cash equivalents at the beginning of the year	3,981.30	4,082.48
<b>Cash and cash equivalents at the end of the year</b>	<b>5,894.29</b>	<b>3,981.30</b>
<b>Components of cash and cash equivalents</b>		
Cash in hand	31.14	27.75
With banks	5,863.15	3,953.55
<b>Total cash and cash equivalents (Note 13)</b>	<b>5,894.29</b>	<b>3,981.30</b>
<b>Summary of significant accounting policies</b>		

2

The accompanying notes form an integral part of the financial statements  
As per our report of even date

**For H L Bansal and CO.**

Chartered Accountants  
FRN. NO. 008563N

**Hira Lal Bansal**  
Partner

M.No. 086990

Place: New Delhi

Date: 30 June, 2021

UDIN: 21086990 DB5924



**For and on behalf of the Board of Directors**  
For Jagsonpal Pharmaceuticals Limited

**Rajpal Singh Kochhar**  
DIN 00059492  
Chairman & Managing Director

**S.K. Dudeja**  
Chief Financial Officer

**Nandita Singh**  
Company Secretary